Related Experiment Video
Updated: Sep 18, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15/IL21 Exhibit Enhanced Activity
Reona Okada1, Jeyshka M Reyes-González1, Constanza Rodriguez1
1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract:
Neuroblastoma is a highly aggressive childhood solid tumor with poor outcomes. Chimeric antigen receptor (CAR) T cells have shown limited efficacy in neuroblastoma, with the best outcomes reported in patients with a low tumor burden, highlighting the need for further CAR optimization. One approach to addressing the high tumor burden involves engineering CAR T cells to release or express transgenic cytokines. However, its systemic toxicity remains an important therapeutic challenge. In this study, we evaluated the efficacy of IL15- and IL21-enhanced glypican 2 (GPC2)-targeted CAR T cells (GPC2-CAR T cells) in targeting high-burden neuroblastoma. Three strategies for expressing the cytokines were evaluated: constitutive secretion (GPC2-CAR + sol.IL15.IL21), constitutive membrane-tethered expression (GPC2-CAR + teth.IL15.IL21), and NFAT-inducible membrane-tethered expression (GPC2-CAR + NFAT.IL15.IL21). Engineered GPC2-CAR T cells were tested in vitro and in vivo using high neuroblastoma burden xenograft models. Additionally, single-cell RNA sequencing was used to profile the effector cells in the tumor microenvironment. All three versions of GPC2-CAR T cells significantly enhanced killing against a high neuroblastoma burden, both in vitro and in vivo, relative to control GPC2-CAR T cells. Mice treated with GPC2-CAR + NFAT.IL15.IL21 exhibited significantly lower anorexia-associated morbidity/mortality. Supporting these data, tumor-infiltrating GPC2-CAR + NFAT.IL15.IL21 developed an immunosuppressive transcriptional profile upon tumor regression, leading to prolonged survival in treated mice. In contrast, GPC2-CAR + teth.IL15.IL21 maintained a proinflammatory transcriptional signature despite near tumor clearance, resulting in hypercytokinemia and death. NFAT-inducible co-expression of tethered IL15/IL21 enhanced GPC2-CAR T-cell function against a high neuroblastoma burden with acceptable tolerability in mice. Further studies are required to validate these findings.
Insights
Engineered chimeric antigen receptor (CAR) T cells targeting GPC2 show promise for high-burden neuroblastoma. An NFAT-inducible cytokine expression strategy improved efficacy and tolerability in preclinical models.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Neuroblastoma is a severe childhood cancer with poor prognosis.
- Current chimeric antigen receptor (CAR) T-cell therapies show limited success in high-tumor-burden neuroblastoma.
- Optimizing CAR T cells, including cytokine enhancement, is crucial for improving treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of glypican 2 (GPC2)-targeted CAR T cells enhanced with interleukin-15 (IL15) and interleukin-21 (IL21) for treating high-burden neuroblastoma.
- To compare three strategies for cytokine expression: constitutive secretion, constitutive membrane-tethered expression, and NFAT-inducible membrane-tethered expression.
- To assess the safety and tolerability of these enhanced CAR T cells in preclinical models.
Main Methods:
- Engineered GPC2-CAR T cells with different IL15/IL21 expression strategies were developed.
- In vitro and in vivo efficacy was tested using high neuroblastoma burden xenograft models.
- Single-cell RNA sequencing was employed to analyze the tumor microenvironment and effector cell profiles.
Main Results:
- All three GPC2-CAR T-cell variants significantly improved tumor killing compared to control CAR T cells.
- The NFAT-inducible GPC2-CAR T-cell group showed reduced morbidity and mortality associated with anorexia.
- NFAT-inducible GPC2-CAR T cells induced an immunosuppressive tumor microenvironment profile post-regression, correlating with prolonged survival.
Conclusions:
- NFAT-inducible co-expression of tethered IL15/IL21 enhances GPC2-CAR T-cell efficacy against high-burden neuroblastoma.
- This strategy demonstrated acceptable tolerability in preclinical models.
- Further research is needed to validate these findings for clinical application.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

